{"analyses":[{"ciLowerLimit":"0.997","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.216","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Ratio of Least square mean","paramValue":"1.10"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18405.23","value":"29016.1"},{"groupId":"OG001","spread":"16894.88","value":"31194"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points to analyze AUC(0-infinity) of niraparib.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Niraparib 300 mg in fasted condition","id":"OG000","title":"FE Niraparib Fasted"},{"description":"Participants received Niraparib 300 mg in fed condition","id":"OG001","title":"FE Niraparib Fed"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic population consisted of all participants who received at least one dose of study drug, with sufficient data available to calculate parameters. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose","title":"Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC[0-infinity]) Following Administration of Niraparib (FE Sub-study)","type":"SECONDARY","unitOfMeasure":"Nanograms*hour per milliliter"}